Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment

Abstract

NEs occurred frequently in this combined dataset and they affected treatment delivery. Identifying patients at high NE risk enables targeted prophylaxis and may avoid dose limitations.

Real-World Impact of Granulocyte-Colony Stimulating Factor on Febrile Neutropenia

“…Although the risk of fn for several chemotherapy regimens has been widely described within the context of clinical trials, only a few studies have described the occurrence of fn in clinical practice [19][20][21][22][23] . Interestingly, the reported incidence of fn associated with specific chemotherapy regimens is higher in clinical practice than in clinical trials 19,21,[23][24][25] .…”

Adherence to Treatment Guidelines in Breast Cancer Care – a Retrospective Analysis of the ‘Organgruppe Mamma der Arbeitsgemeinschaft Gynaekologische Onkologie’

“…High-quality therapy results from the fact that dose reductions or interval prolongation were stated in less than 10% of cases, which implies a high relative dose intensity of the chemotherapy conducted. This is an important indicator for the quality of therapy [6]. The high rate of available predictive factors (ER, PR HER2) is proof of a positive implementation of an evidence-based approach.…”

Risk of mortality in patients with cancer who experience febrile neutropenia

“…3,[8][9][10] FN is associated with significant morbidity and mortality, with estimates of 6.8% to 20% mortality among patients who are hospitalized for FN-related complications and with higher rates observed in patients who have major comorbidities and documented sepsis or shock. 2,[10][11][12] FN and Late Mortality Despite successful management, FN may have an equally important impact on the overall chemotherapy treatment plan, resulting in dose reductions, treatment delays, chemotherapy discontinuation, or a switch to alternative, less toxic, or potentially less effective regimens. 11,13 Myelosuppression continues to represent the major cause of reduced chemotherapy dose intensity.…”

“…2,[10][11][12] FN and Late Mortality Despite successful management, FN may have an equally important impact on the overall chemotherapy treatment plan, resulting in dose reductions, treatment delays, chemotherapy discontinuation, or a switch to alternative, less toxic, or potentially less effective regimens. 11,13 Myelosuppression continues to represent the major cause of reduced chemotherapy dose intensity. In vivo animal studies have demonstrated that relatively small decreases in dose can cut cure rates by 50% or more.…”